Overview

A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses

Status:
Not yet recruiting

Trial end date:
2027-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the efficacy and safety of Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses.

Phase:

Phase 2

Details

Lead Sponsor:

Fujian Cancer Hospital

Treatments:

Lenvatinib
Tislelizumab